Genomic Testing

FOUNDATIONONE®CDx

Our assay for solid tumours including but not limited to: Non-Small Cell Lung Cancer (NSCLC), Colorectal, Breast, Ovarian, and Melanoma
  • INDICATIONS
    NSCLC, CRC, Melanoma, and other solid tumours
  • SAMPLE TYPE
    Formalin-fixed, Paraffin-embedded (FFPE) tissue
  • RESULTS EXPECTED
    2 weeks
What is FoundationOne CDx?

FoundationOne CDx is a validated Comprehensive Genomic Profile that interrogates the entire coding sequence of 324 cancer-related genes plus select introns from 36 genes often rearranged or altered in solid cancers.1

Overview

FoundationOne CDx

  1. A single assay that detects 4 classes of genomic alterations required to comprehensively profile a tumour.1
  2. Targets the entire coding regions of >300 cancer-related genes and select introns of 36 genes frequently rearranged in cancer.1
  3. Quantify emerging genomic signatures, Tumour Mutational Burden (TMB) and Microsatellite Instability (MSI), which may represent highly immunogenic tumours.2,3

LEARN HOW FoundationOne CDx IS DIFFERENT FROM HOTSPOT TESTING

Patients who may benefit from FoundationOne CDx

FoundationOne CDx is a Comprehensive Genomic Profiling service that helps physicians identify potential next steps for patients with cancer by identifying the molecular growth drivers of their cancers.

  1. Patients newly diagnosed with Stage IV rare (or uncommon) solid tumours for whom very limited or no systemic treatment exists in clinical care guidelines and/or pathways
  2. Patients newly diagnosed with aggressive Stage IV solid tumours which have a poor prognosis, very limited response to standard of care, and a high prevalence of actionable genomic alterations
  3. Patients newly diagnosed with carcinoma of unknown primary origin (CUP) or primary anatomic site
  4. Patients with Stage IV solid tumours who have exhausted established guideline‐driven systemic therapy and requisite molecular testing but who maintain adequate functional status
  5. Patients diagnosed with solid tumours whose available biopsy sample proves insufficient to complete requisite molecular testing or whose only specimen was obtained via fine needle aspiration, thoracentesis, paracentesis, or endobronchial ultrasound, thereby placing the patient at risk for additional comorbid procedure(s) to obtain additional tissue

Order FoundationOne CDx

We provide physicians with several options for ordering FoundationOne CDx for patients including fax, and phone. Healthcare providers must first complete a test requisition form to start the process and can expect results within 2 weeks from the time a tissue specimen is received at the lab location.

Order Genomic Test with Your Doctor

Patients

FoundationOne CDx is ordered by your healthcare provider. Our patient info kit has all the information you and your doctor need to discuss FoundationOne CDx testing.

Download Patient Brochure

Health Care Practitioners

FoundationOne®CDx can be ordered by fax, or by phone. Please review and complete the provider resources before ordering.

Order Now